The importance of steatosis in chronic hepatitis C infection and its management: A review

Hepatology Research

Volumn 40, Issue 3, 2010, Pages 237-247

  Cross, Timothy J S ^a   Rashid, Mohammed M ^a   Berry, Philip A ^b   Harrison, Phillip M ^c  

^a DERRIFORD HOSPITAL   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Genotype; Hepatitis C virus; Steatosis; Sustained virological response

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); FATTY ACID; HEPCIDIN; INSULIN; INSULIN RECEPTOR SUBSTRATE; INSULIN RECEPTOR SUBSTRATE 1; INTERLEUKIN 6; METFORMIN; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; PEGINTERFERON ALPHA2A; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PIOGLITAZONE; PLACEBO; RIBAVIRIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANTIVIRAL THERAPY; BODY MASS; CLINICAL TRIAL; DISEASE COURSE; FATTY LIVER; FIBROGENESIS; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERGLYCEMIA; HYPERHOMOCYSTEINEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIPID PEROXIDATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SENESCENCE; TREATMENT OUTCOME; VIRUS GENOME; VIRUS VIRULENCE; WAIST CIRCUMFERENCE;

EID: 77954378905     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2010.00626.x     Document Type: Review

References (93)

1. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004, 126:586-97.
2. Vidali M, Occhino G, Ivaldi A, Rigamonti C, Sartori M, Albano E. Combination of oxidative stress and steatosis is a risk factor for fibrosis in alcohol-drinking patients with chronic hepatitis C. Am J Gastroenterol 2008, 103:147-53.
3. Roffi L, Redaelli A, Colloredo G. Outcome of liver disease in a large cohort of histologically proven chronic hepatitis C: influence of HCV genotype. Eur J Gastroenterol Hepatol 2001, 13:501-6.
4. Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 2002, 36:729-36.
5. Aytug S, Reich D, Sapiro LE, Bernstein D, Begum N. Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology 2003, 38:1384-92.
6. Kawaguchi T, Yoshida T, Harada M. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004, 165:1499-508.
7. Fartoux L, Poujol-Robert A, Guechot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005, 54:1003-8.
8. Hickman IJ, Powell EE, Prins JB. In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. J Hepatol 2003, 39:1042-8.
9. van Dam RM, Hu FB. Lipocalins and insulin resistance: etiological role of retinol-binding protein 4 and lipocalin-2? Clin Chem 2007, 53:5-7.
10. Larter CZ, Farrell GC. Insulin resistance, adiponectin, cytokines in NASH: Which is the best target to treat? J Hepatol 2006, 44:253-61.
11. Graham TE, Yang Q, Bluher M. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006, 354:2552-63.
12. Liu CJ, Chen PJ, Jeng YM. Serum adiponectin correlates with viral characteristics but not histologic features in patients with chronic hepatitis C. J Hepatol 2005, 43:235-42.
13. Petta S, Camma C, Di Marco V. Retinol-binding protein 4: a new marker of virus-induced steatosis in patients infected with hepatitis c virus genotype 1. Hepatology 2008, 48:28-37.
14. Feldstein AE, Canbay A, Angulo P. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003, 125:437-43.
15. Feldstein AE, Canbay A, Guicciardi ME, Higuchi H, Bronk SF, Gores GJ. Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J Hepatol 2003, 39:978-83.
16. Ballesteros AL, Franco S, Fuster D. Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches. Aids 2004, 18:59-66.
17. Adinolfi LE, Ingrosso D, Cesaro G. Hyperhomocysteinemia and the MTHFR C677T polymorphism promote steatosis and fibrosis in chronic hepatitis C patients. Hepatology 2005, 41:995-1003.
18. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001, 33:1358-64.
19. Rubbia-Brandt L, Quadri R, Abid K. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000, 33:106-15.
20. Rubbia-Brandt L, Leandro G, Spahr L. Liver steatosis in chronic hepatitis C: a morphological sign suggesting infection with HCV genotype 3. Histopathology 2001, 39:119-24.
21. Moriya K, Yotsuyanagi H, Shintani Y. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 1997, 78:1527-31.
22. Kumar D, Farrell GC, Fung C, George J. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response. Hepatology 2002, 36:1266-72.
23. Reddy KR, Govindarajan S, Marcellin P. Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin. J Viral Hepat 2008, 15:129-36.
24. Castera L, Hezode C, Roudot-Thoraval F. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis. Gut 2004, 53:420-4.
25. Barba G, Harper F, Harada T. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci USA 1997, 94:1200-5.
26. Moriya K, Fujie H, Shintani Y. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998, 4:1065-7.
27. Perlemuter G, Sabile A, Letteron P. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. Faseb J 2002, 16:185-94.
28. Piodi A, Chouteau P, Lerat H, Hezode C, Pawlotsky JM. Morphological changes in intracellular lipid droplets induced by different hepatitis C virus genotype core sequences and relationship with steatosis. Hepatology 2008, 48:16-27.
29. Serfaty L, Andreani T, Giral P, Carbonell N, Chazouilleres O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol 2001, 34:428-34.
30. Wetterau JR, Aggerbeck LP, Bouma ME. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science 1992, 258:999-1001.
31. Tsutsumi T, Suzuki T, Shimoike T. Interaction of hepatitis C virus core protein with retinoid X receptor alpha modulates its transcriptional activity. Hepatology 2002, 35:937-46.
32. Yamaguchi A, Tazuma S, Nishioka T. Hepatitis C virus core protein modulates fatty acid metabolism and thereby causes lipid accumulation in the liver. Dig Dis Sci 2005, 50:1361-71.
33. de Gottardi A, Pazienza V, Pugnale P. Peroxisome proliferator-activated receptor-alpha and -gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection. Aliment Pharmacol Ther 2006, 23:107-14.
34. Cheng Y, Dharancy S, Malapel M, Desreumaux P. Hepatitis C virus infection down-regulates the expression of peroxisome proliferator-activated receptor alpha and carnitine palmitoyl acyl-CoA transferase 1A. World J Gastroenterol 2005, 11:7591-6.
35. Yasui KHY, Mitsuyoshi H, Tsuji K. Steatosis and intrahepatic expression levels of genes regulating lipid metabolism in Japanese patients with chronic hepatitis C. Hepatology 2008, 48(4):775A. Suppl
36. Allison ME, Wreghitt T, Palmer CR, Alexander GJ. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 1994, 21:1135-9.
37. Knobler H, Schihmanter R, Zifroni A, Fenakel G, Schattner A. Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. Mayo Clin Proc 2000, 75:355-9.
38. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000, 133:592-9.
39. Zein CO, Levy C, Basu A, Zein NN. Chronic hepatitis C and type II diabetes mellitus: a prospective cross-sectional study. Am J Gastroenterol 2005, 100:48-55.
40. Thuluvath PJ, John PR. Association between hepatitis C, diabetes mellitus, and race. a case-control study. Am J Gastroenterol 2003, 98:438-41.
41. White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol 2008, 49:831-44.
42. Hui JM, Sud A, Farrell GC. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected. Gastroenterology 2003, 125:1695-704.
43. Tsochatzis EPG, Koliaraki V, Manesis EK, Mamalaki A, Archimandritis AJ. Serum hepcidin levels are related to viral load and to histological severity of liver lesions in chronic hepatitis C. Hepatology 2008, 48:774A.
44. Mihm S, Fayyazi A, Hartmann H, Ramadori G. Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype. Hepatology 1997, 25:735-9.
45. Asselah T, Boyer N, Guimont MC. Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C. Gut 2003, 52:1638-43.
46. Castera L, Pawlotsky JM, Dhumeaux D. Worsening of steatosis and fibrosis progression in hepatitis C. Gut 2003, 52:1531.
47. Poynard T, Ratziu V, McHutchison J. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003, 38:75-85.
48. Patton HM, Patel K, Behling C. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004, 40:484-90.
49. Rubbia-Brandt L, Fabris P, Paganin S. Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut 2004, 53:406-12.
50. Cross TJ, Calvaruso V, Maimone S. Prospective Comparison of Fibroscan, King's Score and Liver Biopsy for the Assessment of Cirrhosis in Chronic Hepatitis C infection. J Viral Hepat 2009
51. Lok AS, Everhart JE, Chung RT. Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology 2009, 49:1828-37.
52. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Host- and disease-specific factors affecting steatosis in chronic hepatitis C. J Hepatol 1998, 29:198-206.
53. Hui JM, Kench J, Farrell GC. Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J Gastroenterol Hepatol 2002, 17:873-81.
54. Asselah T, Rubbia-Brandt L, Marcellin P, Negro F. Steatosis in chronic hepatitis C: why does it really matter? Gut 2006, 55:123-30.
55. Moucari R, Asselah T, Cazals-Hatem D. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008, 134:416-23.
56. Leandro G, Mangia A, Hui J. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006, 130:1636-42.
57. Hickman IJ, Clouston AD, Macdonald GA. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002, 51:89-94.
58. Clouston AD, Jonsson JR, Purdie DM. Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation. J Hepatol 2001, 34:314-20.
59. Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci USA 1997, 94:2557-62.
60. Okuda M, Li K, Beard MR. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002, 122:366-75.
61. Paradis V, Mathurin P, Kollinger M. In situ detection of lipid peroxidation in chronic hepatitis C: correlation with pathological features. J Clin Pathol 1997, 50:401-6.
62. Houglum K, Venkataramani A, Lyche K, Chojkier M. A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology 1997, 113:1069-73.
63. Teli MR, Day CP, Burt AD, Bennett MK, James OF. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet 1995, 346:987-90.
64. Ratziu V, Giral P, Charlotte F. Liver fibrosis in overweight patients. Gastroenterology 2000, 118:1117-23.
65. Ratziu V, Munteanu M, Charlotte F, Bonyhay L, Poynard T. Fibrogenic impact of high serum glucose in chronic hepatitis C. J Hepatol 2003, 39:1049-55.
66. Raynard B, Balian A, Fallik D. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 2002, 35:635-8.
67. Shintani Y, Fujie H, Miyoshi H. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004, 126:840-8.
68. Larrea E, Garcia N, Qian C, Civeira MP, Prieto J. Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C. Hepatology 1996, 23:210-17.
69. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997, 389:610-14.
70. Halse R, Pearson SL, McCormack JG, Yeaman SJ, Taylor R. Effects of tumor necrosis factor-alpha on insulin action in cultured human muscle cells. Diabetes 2001, 50:1102-9.
71. Paradis V, Perlemuter G, Bonvoust F. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001, 34:738-44.
72. Konrad T, Zeuzem S, Vicini P. Evaluation of factors controlling glucose tolerance in patients with HCV infection before and after 4 months therapy with interferon-alpha. Eur J Clin Invest 2000, 30:111-21.
73. Tanaka H, Shiota G, Kawasaki H. Changes in glucose tolerance after interferon-alpha therapy in patients with chronic hepatitis C. J Med 1997, 28:335-46.
74. Romero-Gomez M, Del Mar Viloria M, Andrade RJ. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005, 128:636-41.
75. Kaserer K, Fiedler R, Steindl P, Muller CH, Wrba F, Ferenci P. Liver biopsy is a useful predictor of response to interferon therapy in chronic hepatitis C. Histopathology 1998, 32:454-61.
76. Bjoro K, Bell H, Hellum KB. Effect of combined interferon-alpha induction therapy and ribavirin on chronic hepatitis C virus infection: a randomized multicentre study. Scand J Gastroenterol 2002, 37:226-32.
77. Akuta N, Suzuki F, Tsubota A. Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors. J Hepatol 2002, 37:831-6.
78. Soresi M, Tripi S, Franco V. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis. Liver Int 2006, 26:1119-25.
79. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003, 38:639-44.
80. Jacobson IM, Brown RS, McCone J. Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. Hepatology 2007, 46:982-90.
81. Platanias LC. The p38 mitogen-activated protein kinase pathway and its role in interferon signaling. Pharmacol Ther 2003, 98:129-42.
82. Giannini E, Ceppa P, Testa R. Steatosis in chronic hepatitis C: can weight reduction improve therapeutic efficacy? J Hepatol 2001, 35:432-3.
83. Elgouhari HCK, Lopez R, Zein NM. Pioglitazone improves early virologic kinetic response to PEG IFN/RBV combination therapy in hepatitis C genotype 1 naive pts. Hepatology 2008, 48(4):383A. Suppl
84. Conjeevaram HBC, McKenna B, Harsh D. A randomized, double blind, placebo-controlled study of PPAR-gamma agonist pioglitazone given in combination with peginterferon and ribavirin in patients with genotype-1 chronic hepatitis C. Hepatology 2008, 48(4):384A. Suppl
85. Walsh MJ, Jonsson JR, Richardson MM. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006, 55:529-35.
86. Persico M, Capasso M, Persico E. Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: Insulin resistance and response to antiviral therapy. Hepatology 2007, 46:1009-15.
87. Romero-Gomez M, Diago M, Andrade RJ. Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology 2009, 50:1702-8.
88. Lerat H, Honda M, Beard MR. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology 2002, 122:352-65.
89. Ohata K, Hamasaki K, Toriyama K. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 2003, 97:3036-43.
90. Moriishi K, Mochizuki R, Moriya K. Critical role of PA28gamma in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis. Proc Natl Acad Sci USA 2007, 104:1661-6.
91. Miyamoto H, Moriishi K, Moriya K. Involvement of the PA28gamma-dependent pathway in insulin resistance induced by hepatitis C virus core protein. J Virol 2007, 81:1727-35.
92. Kumar D, Farrell GC, Kench J, George J. Hepatic steatosis and the risk of hepatocellular carcinoma in chronic hepatitis C. J Gastroenterol Hepatol 2005, 20:1395-400.
93. Pekow JR, Bhan AK, Zheng H, Chung RT. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Cancer 2007, 109:2490-6.